An integrative approach zinc induced integrated stress response as a key driver for β cell failure in human type 2 diabetes
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1050263 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR27151370_1.fastq.gz | Fastqsanger.gz | |||
| SRR27151370_2.fastq.gz | Fastqsanger.gz | |||
| SRR27151371_1.fastq.gz | Fastqsanger.gz | |||
| SRR27151371_2.fastq.gz | Fastqsanger.gz | |||
| SRR27151372_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 12 |
Similar Datasets
Project description:Dysfunctional pancreatic islet β cells are a hallmark of type 2 diabetes (T2D), yet effective therapies to protect these cells from dysfunction are lacking. In this study, through a combination of islet single-cell data from independent cohorts and machine learning, we reveal zinc-induced integrated stress response (ISR) as a potential target for β cell protection. Validating our findings with human embryonic stem cell-derived β cells (SC-β cells) and human primary islets, we confirm that inhibiting zinc transportation shields β cells from exacerbated endoplasmic reticulum stress (ER stress) and concurrent integrated stress response (ISR). Mechanistically, our results discover that elevated zinc transportation exacerbates ER stress, promoting phosphorylation of the eukaryotic translation initiation factor 2 (eIF2α) subunit, thereby initiating ISR, enhancing stress granule formation, and ultimately leading to β cell death as a pivotal pathomechanism for β cell loss. Furthermore, through compound screening targeting zinc transportation with SC-β cells, we discover that low-dose (nanomolar) anisomycin significantly inhibits zinc transportation, preventing β cell loss from various stress-induced cell deaths. Significantly, in vivo administration of anisomycin in mice protects β cells and prevents diabetes induced by streptozotocin (STZ) and type 2 diabetes (high-fat diet, HFD). Collectively, our findings highlight the potency of combining large-scale single-cell data, machine learning, human embryonic stem cell-derived cells, and compound screening to identify potential therapeutic molecules against complex diseases.
2025-06-04 | GSE249735 | GEO
Project description:High-grade osteosarcoma is a tumor with a complex genomic profile, occurring primarily in adolescents with a second peak at middle age. The extensive genomic alterations obscure the identification of genes driving tumorigenesis during osteosarcoma development. In order to identify such driver genes, we integrated DNA copy number profiles (Affymetrix SNP 6.0) of 32 diagnostic biopsies with 84 expression profiles (Illumina Human-6 v2.0) of high-grade osteosarcoma as compared with its putative progenitor cells, i.e. mesenchymal stem cells (n=12) or osteoblasts (n=3). In addition, we performed paired analyses between copy number and expression profiles of a subset of 29 patients for which both DNA and mRNA profiles were available. Integrative analyses were performed in Nexus Copy Number software and statistical language R. Paired analyses were performed on all probes detecting significantly differentially expressed genes in corresponding LIMMA analyses. For both non-paired and paired analyses, copy number aberration frequency was set to >35%. Non-paired and paired integrative analyses resulted in 45 and 101 genes, respectively, which were present in both analyses using different control sets. Paired analyses detected >90% of all genes found with the corresponding non-paired analyses. Remarkably, approximately twice as many genes as found in the corresponding non-paired analyses were detected. Affected genes were intersected with differentially expressed genes in osteosarcoma cell lines, resulting in 31 new osteosarcoma driver genes. Cell division related genes, such as MCM4 and LATS2, were overrepresented and genomic-instability was predictive for metastasis-free survival, suggesting that deregulation of the cell cycle is a driver of osteosarcomagenesis. This SuperSeries is composed of the following subset Series: GSE28974: Genome-wide gene expression profiling of mesenchymal stem cells GSE33153: Copy number analysis of high-grade osteosarcoma GSE33382: Genome-wide gene expression analysis of high-grade osteosarcoma For data processing, we refer to the individual series. We performed both non-paired and paired integrative analyses on SNP and gene expression data. Non-paired integrative analysis was performed by importing lists of differentially expressed genes into the Copy Number module of Nexus software version 5 (BioDiscovery, CA). Based on the length of the gene list, Nexus software performs a Fisher's exact test in order to determine whether the number of differentially expressed genes in a specific region with a significant copy number alteration is larger than expected by chance. Genes present in such regions of copy number alteration with FDR-adjusted P-values (Q-bounds in Nexus software) < 0.05 were returned from this integrative analysis. Nexus software only reports genes which are both gained and overexpressed, or both deleted and downregulated. For the paired integrative analysis, copy number data of all autosomal overlapping genes between the copy number and gene expression arrays were exported from Nexus software, and converted into a binary file containing all genes with a gain (1) and no gain (0), and a similar binary file for losses. As in the non-paired integrative analysis, we did not apply any restrictions on the size of copy number alterations. Gene expression data of each probe for each sample were normalized against average gene expression of the corresponding probes over all control samples (either expression data from 12 MSCs, or from 3 osteoblasts). This was performed by subtracting the average expression of the control samples from the expression levels of the sample of interest, since these are log-transformed expression values. For both analyses, only genes that were significantly differentially expressed between the 84 osteosarcoma samples and the specific control set were analyzed, in order to make sure that no genes returned from the integrative analysis were not significantly differentially expressed. Subse quently, genes that overlapped between the copy number binary files and that matched the fold change of expression (upregulation for genes with gains, and downregulation for genes with losses) were returned.
2012-03-27 | E-GEOD-33383 | biostudies-arrayexpress
Project description:Integrative Gene Regulatory Network Analysis Discloses Key Driver Genes of Fibromuscular Dysplasia
| PRJNA1122869 | ENA
Project description:Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes (ALK)
| PRJNA512029 | ENA
Project description:Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes (PHOX2B)
| PRJNA512028 | ENA
Project description:Integrative Gene Regulatory Network Analysis Discloses Key Driver Genes of Fibromuscular Dysplasia
| PRJNA1122870 | ENA
Project description:High-grade osteosarcoma is a tumor with a complex genomic profile, occurring primarily in adolescents with a second peak at middle age. The extensive genomic alterations obscure the identification of genes driving tumorigenesis during osteosarcoma development. In order to identify such driver genes, we integrated DNA copy number profiles (Affymetrix SNP 6.0) of 32 diagnostic biopsies with 84 expression profiles (Illumina Human-6 v2.0) of high-grade osteosarcoma as compared with its putative progenitor cells, i.e. mesenchymal stem cells (n=12) or osteoblasts (n=3). In addition, we performed paired analyses between copy number and expression profiles of a subset of 29 patients for which both DNA and mRNA profiles were available. Integrative analyses were performed in Nexus Copy Number software and statistical language R. Paired analyses were performed on all probes detecting significantly differentially expressed genes in corresponding LIMMA analyses. For both non-paired and paired analyses, copy number aberration frequency was set to >35%. Non-paired and paired integrative analyses resulted in 45 and 101 genes, respectively, which were present in both analyses using different control sets. Paired analyses detected >90% of all genes found with the corresponding non-paired analyses. Remarkably, approximately twice as many genes as found in the corresponding non-paired analyses were detected. Affected genes were intersected with differentially expressed genes in osteosarcoma cell lines, resulting in 31 new osteosarcoma driver genes. Cell division related genes, such as MCM4 and LATS2, were overrepresented and genomic-instability was predictive for metastasis-free survival, suggesting that deregulation of the cell cycle is a driver of osteosarcomagenesis. This SuperSeries is composed of the SubSeries listed below.
2012-03-28 | GSE33383 | GEO
Project description:Failure in intracellular zinc accumulation is a key process in prostate cancerogenesis. Although prostate cancer cells can accumulate zinc after long-term exposure, chronic zinc oversupply may accelerate prostate carcinogenesis or chemoresistance. As a model of prostate cancerogenesis, long-term zinc-treated (zinc accumulating) cell lines 22Rv1, and PC-3 were used. In this dataset we investigated how long-term zinc treatment is associated with changes of cell proteome in these cells as determined by LC-MS. Preparation of long-term zinc-treated cells is described in Holubova et al., 2014, and Raudenska et al, 2019.
2024-09-11 | PXD046410 | Pride
Project description:UNCOVERING VULVAR CARCINOMA: AN INTEGRATIVE APPROACH
| PRJNA343113 | ENA
Project description:Type 2 diabetes is associated with defective insulin secretion and reduced β-cell mass. Available treatments provide a temporary reprieve, but secondary failure rates are high, making insulin supplementation necessary. Reversibility of b-cell failure is a key translational question. Here, we reverse-engineered and interrogated pancreatic islet-specific regulatory networks to discover T2D-specific subpopulations characterized by metabolic-inflexibility and endocrine-progenitor/stem cell features. Single-cell gain- and loss-of-function and glucose-induced Ca++ flux analyses of top candidate MR in islet cells validated transcription factor BACH2 and associated epigenetic effectors as a key driver of T2D cell states. BACH2 knockout in T2D islets reversed cellular features of the disease, restoring a non-diabetic phenotype. BACH2-immunoreactive islet cells increased ~4-fold in diabetic patients, confirming the algorithmic prediction of clinically relevant subpopulations. Treatment with a BACH inhibitor lowered glycemia and increased plasma insulin levels in diabetic mice, and restored insulin secretion in diabetic mice and human islets. The findings suggest that T2D-specific populations of failing b-cells can be reversed and indicate pathways for pharmacological intervention, including via BACH2 inhibition.
2021-11-11 | GSE98887 | GEO